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Background: Over the past decade, well tolerated second-line thera-
pies for advanced non–small-cell lung cancer have been approved 
including erlotinib and pemetrexed in addition to docetaxel. We 
hypothesize that the introduction of less toxic chemotherapy has 
increased treatment of advanced non–small-cell lung cancer result-
ing in improved survival.
Methods: The BC Cancer Agency provides cancer care to 4.5 mil-
lion. A retrospective review was conducted of all referred Stage IIIB/
IV patients in four 1-year time cohorts; C1 baseline (1998) and 6 
months after the provincial approval of C2 docetaxel (2001), C3 erlo-
tinib (2006), and C4 pemetrexed (2007).
Results: Two-thousand six-hundred and twenty-three patients 
were referred and 720 had systemic therapy. Characteristics: M/F 
55%/45%, median age 67 (33–101), ECOG PS <=1/>=2/unknown 
33%/56%/11%, squam/nonsquam/NOS 18%/41%/41%. More 
patients received first-line chemotherapy over time; 16%, 23%, 34%, 
and 33% C1–C4 respectively. In C1–C4 uptake of second line (21%, 
27%, 37% and 55%) increased. Second-line docetaxel was frequently 
used in C2 (51%) but usage decreased in C4 to 7% versus erlotinib 
50% and pemetrexed 26%. The median overall survival in the best 
supportive care group remained stable over time; however, increased 
use of systemic therapy was associated with improved survival C1 
9.4 m versus C4 11.8 m (p = 0.023).
Conclusions: This population-based data set represents the trend of 
treatments over time at community and tertiary care cancer treatment 
sites. Over a 10-year period an increased proportion of patients were 
treated with first-line chemotherapy and an even greater number with 
second-/third-line treatment with an associated improvement in over-
all survival.
Key Words: Non–small-cell lung cancer, Second line, Predictors, 
Docetaxel, Pemetrexed, Erlotinib
(J Thorac Oncol. 2014;9: 1180–1186)
In 2013, 228,190 patients were diagnosed and 159,480 died from lung cancer in the United States.1 Although the statis-
tics are disconcerting, in the past 15 years, many advances 
have improved the outlook of patients diagnosed with meta-
static non–small-cell lung cancer (NSCLC). From the adop-
tion of second- and third-line chemotherapy to maintenance 
options to the use of targeted therapies in the frontline setting, 
the landscape of NSCLC is evolving.
First-line systemic treatment for NSCLC traditionally 
has been a platinum doublet based on evidence from multi-
ple clinical trials.2–4 A significant change in upfront therapy, 
however, has been the introduction of molecular biomarker 
screening in non-squamous NSCLC for mutations in the epi-
dermal growth factor receptor (EGFR) and anaplastic lym-
phoma kinase (ALK) fusions.5–10 Although these two groups 
represent only a small fraction of the advanced NSCLC popu-
lation, this holds promise for how treatment decisions will be 
made in the future.
Second-line treatment for NSCLC has been established 
since the publications by Fossella et al11 and Shepherd et al12 
in 2000 utilizing docetaxel in the salvage setting. A benefit 
in median survival of 2.4 months was seen with docetaxel 
compared with best supportive care (BSC). Docetaxel was 
associated with toxicity concerns particularly with respect 
to neutropenia and in clinical practice was used cautiously. 
Pemetrexed was approved by the Food and Drug Adminstration 
(FDA) in 2004 based on a comparison trial against docetaxel.13 
Significantly, fewer side effects were observed in the peme-
trexed group which positively influenced uptake and usage. 
The indication for pemetrexed was revised in 2007 to include 
only patients with non squamous histology based on subse-
quent studies.14,15 In 2004, based on the results of a randomized 
phase III study of erlotinib versus placebo conducted in the 
second- and third-line setting, BR21, erlotinib also received 
FDA approval.16 These three options became the standard of 
care in the second- and third-line setting of advanced NSCLC, 
respectively.
Maintenance chemotherapy has now been incorpo-
rated into the treatment paradigm.17 Maintenance pemetrexed 
has been associated with improvements in progression-free 
and overall survival compared with placebo after an upfront 
platinum doublet.18,19 Similarly, erlotinib demonstrated a pro-
gression-free survival improvement in all fit non-progressors 
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and overall survival benefit in those with stable disease post-
platinum doublet compared with placebo.20,21 Pemetrexed and 
erlotinib maintenance therapy have been available at British 
Columbia Cancer Agency (BCCA) for patients since 2009 and 
2010, respectively.
Although molecular therapy has revolutionized the 
way we approach NSCLC, it only benefits a minority of 
patients. Similarly, in practice, maintenance therapy has 
been difficult to administer to the wider group of NSCLC 
patients because of issues with performance status and 
patients desire for a chemotherapy “holiday”. Many patients 
in the current spectrum receive standard second line therapy 
for their disease.
The use of these drugs in NSCLC has generally fol-
lowed FDA approval, which facilitates reimbursement for 
oncology drugs in the United States. Within Canada, a single 
payer system exists and decisions about implementation are 
made at the provincial level. In British Columbia, access to 
second-line agents, docetaxel, erlotinib, and pemetrexed, 
occurred in December 2000, October 2005, and June 2007, 
respectively. Because of the centralized nature of the system, 
the implementation of new treatment guidelines was consis-
tent throughout the geographic distribution.
We performed a population-based study to assess the 
evolution of NSCLC therapy with the introduction of second-
line therapies. Our goal was to evaluate the uptake of second-
line treatment, assess predictors of delivery of second-line 
therapy, and review the impact on outcomes.
MATERIALS AND METHODS
The BCCA provides cancer care to 4.5 million residents 
and maintains a cancer registry that allows population-based 
analyses. Reporting to the Canadian Cancer Registry indicates 
that of all the patients diagnosed with lung cancer in the prov-
ince over the past decade, 65% are referred for care at one 
of the six BCCA cancer centers. Based on recent reporting 
that includes stage in both referred and non-referred patients, 
approximately 80% of the advanced population is referred. 
Chemotherapy protocols are approved through a central pro-
cess and adopted province wide simultaneously.
A retrospective chart review was conducted of all 
patients referred to the BC Cancer Agency with stage IIIB 
or IV NSCLC per American Joint Committee on Cancer 
version 6 using the Outcome and Surveillance Integrated 
System (OaSIS). Patients with a prior malignancy within 
5 years were excluded. Four 1-year time cohorts were cre-
ated to reflect the approval of second-line chemotherapy for 
NSCLC. Cohort 1 was a baseline cohort and was selected 
from January to December 1998 (C1). Cohort 2 was from 
May 2001 to April 2002, 6 months after the provincial fund-
ing of second-line docetaxel (C2). Cohort 3 was from March 
2006 to February 2007; 6 months after the provincial funding 
of second-line erlotinib (C3). Cohort 4 was from November 
2007 to October 2008, 6 months after the provincial funding 
of second-line pemetrexed (C4).
Data were collected on baseline characteristics 
including age, gender, Eastern Cooperative Group (ECOG) 
performance status (PS), smoking status, histology, and 
ethnicity. Ethnicity was defined as “Asian” versus “non-
Asian”. An Asian subject was defined as having common 
ancestry of any country in Asia. This was determined using 
multiple factors: comparison with a previously validated 
Asian surname list, clinician’s dictated consultations, and/
or the requirement of an Asian language translator. All other 
patients constitute the non-Asian cohort. Systemic treat-
ment details including PS at start of line of chemotherapy, 
type of chemotherapy, number of cycles were collected. 
Ethical approval for the study was obtained from the gov-
erning research ethics board.
Univariate analyses were conducted using the χ2 tests, 
Fisher’s exact tests, and Kruskal-Wallis tests, respectively. 
Logistical regression was employed for the multivariate analy-
sis for predictors of second-line chemotherapy. Survival was 
compared using the Kaplan-Meier method and log rank test. 
Cox regression analysis was utilized for the multivariate anal-
ysis of overall survival. Statistical analysis completed using R 
version 3.0.1.
RESULTS
Cohort Characteristics
In all four cohorts, 2623 patients with stage IIIB/IV 
NSCLC were identified; 555 in C1 (January to December 
1998), 613 in C2 (May 2001 to April 2002), 688 in C3 (March 
2006 to February 2007) and 750 in C4 (November 2007 to 
October 2008). In patients who received BSC, the median age 
was 68, 70, 72, and 71, respectively, sex, histology, and eth-
nicity distribution was similar in all years (Table 1). Smoking 
status and ECOG in the BSC groups differed across years; 
however, there were a significant number of unknown status 
in 1998. In the chemotherapy-treated group, the median ages 
were 59, 60, 63, and 63, respectively. Sex, histology, ethnic-
ity, and smoking status were not different across years but 
ECOG did differ; however, there were a significant number of 
unknown status in 1998.
The proportion of patients who received first-line che-
motherapy in these four cohorts were 16%, 23%, 34%, and 
33% respectively (Table 2). There was a shift from the usage 
in C1 of platinum/vinorelbine to C4 platinum/gemcitabine. 
Second-line treatment increased over time 21%, 27%, 37%, 
and 55%, respectively. In C1 the most common agent used 
was docetaxel (48%) and in C4 EGFR tyrosine kinase inhibi-
tor (TKIs) (50%) followed by pemetrexed (26%). The propor-
tion of patients received third-line chemotherapy was stable 
over the four cohorts. Docetaxel was favored in C1 and EGFR 
TKIs in C4.
Overall Survival
Median overall survival of patients who received BSC 
in the four time cohorts did not differ significantly, 3.9, 4.0, 
3.1, and 3.2 m (p = 0.136; Fig. 1A). In patients who were 
treated with chemotherapy, survival increased over time,9.4, 
9.8, 11.0, and 11.8 m (p = 0.023; Fig. 1B). In the whole popu-
lation, the median survival with BSC was 3.51 m, first-line 
chemotherapy only 7.9 m and second-line chemotherapy or 
greater 17 m (p < 0.001).
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Logistic Regression for Predictors 
of Second-Line Therapy
Logistic regression was conducted using the population 
that had received first-line treatment to determine predictors 
of second-line treatment. Age, gender, histology, PS, ethnicity, 
chemotherapy type and time cohort were included as variables 
(Table 3). Younger age, better PS, Asian ethnicity, first-line 
third generation platinum doublet treatment, and later time 
cohort (2007) were associated with delivery of second-line 
chemotherapy.
Cox Regression for Predictors of Survival
Cox regression modeling for overall survival was con-
ducted. Age, gender, histology, PS, ethnicity, chemother-
apy treatment, and time cohort were included as variables 
(Table 4). Older age, female sex, squamous histology, better 
PS, and chemotherapy treatment in later time cohorts was pre-
dictive of better overall survival.
DISCUSSION
Our study confirms that the increased uptake of sys-
temic therapy for advanced NSCLC results in an increased 
proportion of patients treated with chemotherapy, which con-
fers a significant survival benefit.
This study is an interesting series of snapshots of the 
practice in BC over time. There was a notable increase in the 
use of first-line chemotherapy for advanced NSCLC from 
16% in 1998 to 33% in 2007. In comparison, a Surveillance, 
Epidemiology, and End Result (SEER) study reviewing prac-
tices in the United States through the 1990s noted a first-line 
treatment rate of 26%.22 Of the patients who did not receive 
chemotherapy, 36% were never seen by medical oncology, 
which differed according to race, geographic location, and 
treatment at a teaching hospital. Our review of referral pat-
terns in 2009 indicates that 55% of patients referred are seen 
by medical oncology of which 57% receive chemotherapy.23 
Geographic location (rural versus urban) did not influence 
referral patterns in BC.
A retrospective review of two institutions in Ontario 
over time noted treatment rates with systemic therapy of 20% 
in 1998 and 42% in 2008.24 In the US, a review of patterns at 
four health maintenance organizations (HMOs) from 2000 to 
2007 indicated a chemotherapy treatment rate of 52% in 2000 
and 59% in 2007.25 They observed an association between 
socioeconomic status and the likelihood of chemotherapy 
delivery. A recent study conducted at a single US institution 
observed first-line treatment rates of 49%.26 In this study, the 
type of insurance was associated with use of chemotherapy. 
The denominator in both of the latter studies was patients with 
a diagnosis of advanced NSCLC within their HMOs and insti-
tution, respectively.
The lower proportion of patients treated in BC may 
reflect the population-based nature of our study as it included 
a significant proportion of elderly, less fit patients seen in 
community and academic centers. Many patients received 
TABLE 1.  Baseline Characteristics of Patients Who Received Best Supportive Care (BSC) Versus Chemotherapy by Year of 
Diagnosis
C1 1998 C2 2001 C3 2006 C4 2007
BSC  
(n = 464)
Chemo  
(n = 91)
BSC  
(n = 485)
Chemo  
(n = 146)
BSC  
(n = 453)
Chemo  
(n = 235)
BSC  
(n = 501)
Chemo  
(n = 249)
p across 
years BSC
p across years 
chemotherapy
Median age 
(range)
68 (38–93) 59 (36–84) 70 (39–96) 60 (35–83) 72 (37–95) 63 (33–86) 71 (43–101) 63 (34–86) <0.005 <0.005
Gender (female/ 
male)
199/265 41/50 198/287 81/65 200/253 125/110 213/288 123/126 0.78 0.38
Histology 0.48 0.22
  Squamous 102 (22%) 13 (14%) 115 (24%) 20 (14%) 84 (19%) 41 (17%) 71 (14%) 22 (9%)
  Non-squamous 229 (49%) 58 (64%) 200 (41%) 91 (62%) 156 (34%) 108 (46%) 139 (28%) 94 (38%)
  Unknown 133 (29%) 20 (22%) 170 (35%) 35 (24%) 213 (47%) 86 (37%) 291 (58%) 133 (53%)
Smoking status 0.006 0.25
  Current 43 (10%) 9 (10%) 253 (53%) 64 (44%) 182 (40%) 90 (38%) 215 (43%) 88 (35%)
  Former 30 (6%) 15 (16%) 170 (35%) 61 (42%) 205 (45%) 107 (45%) 214 (43%) 109 (44%)
  Never 6 (1%) 7 (8%) 34 (7%) 17 (11%) 43 (9%) 35 (15%) 44 (9%) 50 (20%)
  Unknown 385 (83%) 60 (66%) 28 (6%) 4 (3%) 23 (6%) 3 (2%) 28 (5%) 2 (1%)
Eastern Cooperative Group Performance Status 0.003 0.98
  0–1 83 (18%) 34 (37%) 129 (27%) 88 (60%) 136 (30%) 139 (59%) 120 (24%) 148 (59%)
  ≥2 144 (31%) 23 (25%) 355 (73%) 55 (38%) 315 (69%) 92 (39%) 381 (76%) 92 (37%)
  Unknown 237 (51%) 34 (38%) 1 3 (2%) 2 (1%) 4 (2%) - 9 (4%)
Ethnicity 0.053 <0.005
  Asian 28 (6%) 7 (8%) 33 (7%) 7 (5%) 48 (11%) 29 (12%) 42 (8%) 44 (18%)
  Other 436 (94%) 84 (92%) 452 (93%) 139 (95%) 405 (89%) 206 (88%) 459 (92%) 205 (82%)
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palliative radiotherapy only for symptomatic management of 
their disease. However, because of the single payer system, 
there were no bias introduced with respected to financial 
accessibility of care and may present a more realistic picture 
of treatment rates in advanced NSCLC.
Although first-line chemotherapy use was limited, once 
patients were deemed chemotherapy eligible and treated, cli-
nicians offered second-line therapy increasing as it became 
available over time. In our baseline cohort, before the trials 
on docetaxel were published and the drug was widely avail-
able, 21% of patients received second-line therapy. By 2007, 
with the options of docetaxel, erlotinib, and pemetrexed, the 
treatment proportion had risen to 55%. Similarly, a study con-
ducted by the University of Texas (UT) Southwestern Medical 
Center found that 49% of patients received second-line ther-
apy although that increased to 67% if the disease was stable 
after four to six cycles of first-line treatment.27 The study by 
Fidias et al.,28 designed to assess immediate versus delayed 
maintenance docetaxel after patients achieved a minimum 
of stable disease with four to six cycles of first-line platinum 
doublet therapy, also offers a comparison. The delayed arm 
represents a treatment paradigm similar to second-line treat-
ment and in this arm 62.8% of patients were able to receive 
drug. Considering that our population in 2007 included 37% 
PS greater than or equal to 2, our rates of second-line treat-
ment were reasonable.
The increased use of second-line treatment paralleled 
the availability of the drug in the province. There was utiliza-
tion of agents before their official funding date as a compas-
sionate access mechanism was in place for access to drugs 
before rigorous review for provincial funding. Accordingly, 
there was some usage of docetaxel in 1998, which increased in 
2001. The availability of less toxicity EGFR TKIs and peme-
trexed quickly changed patterns of practice. In BC the most 
often used agent in the second- and third-line setting were 
EGFR TKIs. The increase in the Asian population and the 
association of response to EGFR TKIs with clinical features 
before mutation testing became routine may have impacted 
practice.29,30 It also reflects the tolerability of the class of tar-
geted agents.16 Overall, uptake of second-line therapy was 
prompt across the province and reflected in the proportion of 
patients who received treatment.
We examined predictive factors for delivery of second-
line chemotherapy. Not surprisingly, in multivariate analysis, 
fit, younger patients were more likely to receive treatment. 
We also noted that Asian ethnicity predicted for second line, 
TABLE 2.  Description of Types of Chemotherapy Administered in First, Second and Third Line by Year of Diagnosis (p Value 
Across Years)
C1 1998 C2 2001 C3 2006 C4 2007
p valueN 565 631 688 750
First line n (%) 91 (16%) 146 (23%) 235 (34%) 249 (33%) <0.005
Median number of cycles 3 4 3 4
Type
  Platinum/etoposide 10 (11%) 17 (12%) 24 (10%) 27 (11%)
  Platinum/taxane 5 (6%) 5 (3%) 31 (13%) 18 (7%)
  Platinum/vinorelbine 64 (70%) 104 (71%) 48 (21%) 31 (12%)
  Platinum/gemcitabine — — 78 (33%) 111 (45%)
  Epidermal growth factor receptor TKI — — 21 (9%) 21 (8%)
  Single agent/other 12 (13%) 20 (14%) 33 (14%) 41 (17%)
Second line n (%) 19 (21%) 39 (27%) 88 (37%) 137 (55%) <0.005
Median number of cycles 4 4 3 3
Type
  Platinum doublet 5 (26%) 5 (13%) 21 (24%) 16 (12%)
  Docetaxel 9 (47%) 20 (51%) 15 (17%) 9 (7%)
  Epidermal growth factor receptor TKI — 11 (28%) 33 (38%) 68 (50%)
  Pemetrexed — — 13 (15%) 36 (26%)
  Single agent/other 5 3 (8%) 6 (6%) 8 (5%)
Third line n (%) 9 (47%) 15 (38%) 32 (36%) 62 (45%) 0.504
Median number of cycles 3 2 2 3
Type
  Platinum doublet 1 (11%) 1 (7%) 3 (9%) 1 (2%)
  Docetaxel 6 (67%) — 2 (6%) 4 (6%)
  Epidermal growth factor receptor TKI — 11 (73%) 18 (57%) 34 (55%)
  Pemetrexed — — 6 (19%) 15 (24%)
  Single agent/other 2 (22%) 3 (20%) 3 (9%) 8 (13%)
TKI, tyrosine kinase inhibitor.
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which may reflects physician attitudes regarding EGFR TKIs 
and clinical predictors. Treatment aspects were also identified 
as predictors including receiving a first-line third generation 
platinum doublet. Treatment in a later time cohort was also a 
positive predictor reflecting the availability of suitable agents 
for effective second-line treatment and physician uptake of 
additional treatment options.
Other retrospective studies have also identified predic-
tors of second-line treatment. Hensing et al.31 followed 230 
patients who had been treated within the context of a first-
line platinum doublet clinical trial. They determined that good 
baseline PS, female gender, non-squamous histology, and two 
or more cycles of first-line treatment predicted for further che-
motherapy. A review of patients treated in Greece correlated 
second-line therapy use with good PS, stage IIIB disease, 
response to first-line treatment and late termination of first-
line treatment.32 A retrospective study in Texas including 406 
patients found that insurance type, number of first-line cycles, 
and prechemotherapy palliative radiotherapy were associated 
with second-line administration.27 Similarities exist between 
all studies in that our results point to a subgroup of patients 
with a better overall prognosis and therefore a higher likeli-
hood to receive further treatment.
Multivariate analysis of overall survival confirms the 
benefit of second-line therapy and the increased therapeutic 
options over time. Older age, female sex, squamous histology, 
and good PS were also associated with better outcomes. We 
hypothesized that older patients may present with more indo-
lent disease than their younger counterparts. Female sex and 
good PS are well known positive prognostic indicators.33,34 In 
the context of studies conducted since the utilization of sec-
ond-line treatment, Yu et al.24 found that treatment with che-
motherapy (both first and second line) and later time cohorts 
predicted for better survival. They also identified a history of 
smoking and multiple metastatic sites as negative prognostic 
factors. The UT Southwestern group concluded that the num-
ber of cycles of first-line chemotherapy and administration of 
second-line were associated with better survival outcomes.27 
The benefits of chemotherapy and specifically second-line 
treatment on patient outcomes are substantial, even in mixed 
population of patients including elderly individuals and those 
with poor functional status.
There are limitations in our retrospective review. Our 
dataset in 1998 was missing smoking history and PS because 
transition to electronic medical records was incomplete; how-
ever, the remaining data points were collected routinely for 
reporting to the Canadian Cancer Registry. We also could not 
control for the possibility of stage migration with the greater 
availability of computed tomography (CT) scans and positron 
TABLE 3.  Logistic Regression for Predictors of Second-Line 
Chemotherapy Delivery
Second-Line Chemotherapy OR p Value
Older age 0.974 0.002
Gender
  Female 1
  Male 0.983 0.922
Histology
  Squamous cell carcinoma 1
  Non-squamous 1.33 0.294
  NOS 0.967 0.905
Eastern Cooperative Group performance status
  0–1 1
  ≥2 0.493 <0.001
Ethnicity
  Asian 1
  Non-Asian 0.382 <0.001
First-line chemotherapy
  Third generation platinum doublet 1
  Other 0.68 0.04
Time cohort
  C1 1998 1
  C2 2001 0.961 0.914
  C3 2006 1.853 0.073
  C4 2007 4.14 <0.001
Younger age, better performance status, Asian ethnicity, first-line third generation 
platinum doublet treatment and later time cohort were associated with delivery of 
second-line chemotherapy.
FIGURE 1.  Overall survival by year. A, best supportive care. 
(B) chemotherapy.
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emission tomography (PET) scans over time. Our strengths 
are the centralized cancer care that ensures provincial imple-
mentation of guideline changes and the ability to evaluate rec-
ommended therapies for NSCLC on a population basis.
In conclusion, our population-based study demonstrates 
an improvement in overall survival in advanced NSCLC patients 
with the increased utilization of first- and second-line systemic 
therapy. This confirms the advances seen in clinical trials popu-
lations over the past decade. As options for treatment of NSCLC 
expand with routine screening for molecular subtypes of NSCLC 
and use of appropriately targeted therapies, we anticipate that the 
outlook for lung cancer will continue to improve.
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